RxDoctor Payments DataLook up a doctor →

Joy Schechtman, DO

Rheumatology · Peoria, AZNPI 1649244716

Payments from drug & device makers

$2,100,675in general payments, 2019–2025

Across 2,951 payments — averaging $711.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$616K
  • AbbVie$567K
  • Amgen$182K
  • UCB, Inc.$107K
  • Lilly USA, LLC$94K
  • Boehringer Ingelheim$75K
  • plus $460K from 54 others
$9,373in research payments, 2019–2025

Across 8 payments — averaging $1171.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biocon Biologics Inc$9K
  • Eli Lilly$26

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis71$615,676
AbbVie589$566,703
Amgen(2 entities)436$181,919
UCB, Inc.289$107,309
Lilly USA, LLC256$93,647
Boehringer Ingelheim123$75,241
Hexal AG55$56,774
Mallinckrodt Hospital Products Inc.119$54,842
Eli Lilly11$52,431
AstraZeneca(2 entities)146$51,823
Johnson & Johnson(2 entities)145$35,632
Sanofi48$26,325
Pfizer114$23,263
Bristol Myers Squibb33$22,854
Radius Health, Inc.66$22,497
Janssen Research & Development, LLC23$19,498
E.r. Squibb & Sons, L.L.C.64$14,740
Janssen Scientific Affairs, LLC17$13,557
GSK70$13,365
UCB SA2$12,687
Mallinckrodt Enterprises LLC26$12,249
Sanofi US Services Inc.37$11,960
Averitas Pharma Inc.7$5,363
Aurinia Pharma U.S., Inc.8$3,610
Genentech USA, Inc.22$2,103
Pacira Therapeutics, Inc.16$1,561
Actelion Pharmaceuticals US, Inc.20$499
ANI Pharmaceuticals, Inc.23$372
Fresenius Kabi USA, LLC13$296
Merck11$272
Sobi, Inc14$270
Genentech, Inc.3$259
Organon7$135
Antares Pharma, Inc.26$115
Abbott4$113
Kyowa Kirin, Inc.3$81
Tersera Therapeutics LLC4$75
Kiniksa Pharmaceuticals, Ltd.3$53
Octapharma USA, Inc.1$42
Kiniksa Pharmaceuticals International, PLC2$36
Nevro Corp.2$34
Pacira Pharmaceuticals Incorporated1$30
Biogen1$27
Zyla Life Sciences, Inc.2$26
Bioventus LLC1$23
Boston Scientific1$23
Takeda Pharmaceuticals U.S.A., Inc.1$20
Ultragenyx Pharmaceutical Inc.1$20
Celltrion USA Inc.1$19
Ascend Therapeutics US, LLC1$18
Gilead1$18
Scilex Pharmaceuticals Inc.1$18
Invivyd Inc1$18
Hikma Pharmaceuticals USA1$18
Tonix Medicines, Inc.1$17
Eisai Inc.1$17
Arcutis Biotherapeutics, Inc.1$16
Medexus Pharma, Inc.1$15
Mylan Institutional Inc.1$14
Avanos Medical1$14

How this compares

$2,100,675 in reported general payments places this provider in the 85th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona

Medicare billing

Part B allowed, 2024
$12,826,609
Medicare patients
1,184
Services billed
846,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →